You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethoxyflurane
Accession NumberDB01028  (APRD00744)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAn inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180)
Structure
Thumb
Synonyms
Methoflurane
Methoxyfluoran
Methoxyfluran
Methoxyfluranum
Methyl 1,1-difluoro-2,2-dichloroethyl ether
Metoxiflurano
Penthrane
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PenthraneAbbott Laboratories
Brand mixturesNot Available
SaltsNot Available
Categories
UNII30905R8O7B
CAS number76-38-0
WeightAverage: 164.966
Monoisotopic: 163.960726574
Chemical FormulaC3H4Cl2F2O
InChI KeyInChIKey=RFKMCNOHBTXSMU-UHFFFAOYSA-N
InChI
InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3
IUPAC Name
2,2-dichloro-1,1-difluoro-1-methoxyethane
SMILES
COC(F)(F)C(Cl)Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkyl ethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are alkyl groups.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassEthers
Sub ClassDialkyl ethers
Direct ParentDialkyl ethers
Alternative Parents
Substituents
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Alkyl chloride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationFor use in the induction and maintenance of general anesthesia
PharmacodynamicsMethoxyflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mechanism of actionMethoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor and the glycine receptor.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=3600 mg/kg (Orally in rats). Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9921
Caco-2 permeable+0.6119
P-glycoprotein substrateNon-substrate0.8535
P-glycoprotein inhibitor INon-inhibitor0.9588
P-glycoprotein inhibitor IINon-inhibitor0.9203
Renal organic cation transporterNon-inhibitor0.9227
CYP450 2C9 substrateNon-substrate0.7959
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6542
CYP450 1A2 substrateNon-inhibitor0.6508
CYP450 2C9 inhibitorNon-inhibitor0.8587
CYP450 2D6 inhibitorNon-inhibitor0.9407
CYP450 2C19 inhibitorNon-inhibitor0.6081
CYP450 3A4 inhibitorNon-inhibitor0.9753
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8956
Ames testNon AMES toxic0.9132
CarcinogenicityCarcinogens 0.7261
BiodegradationNot ready biodegradable0.9737
Rat acute toxicity1.6296 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9515
hERG inhibition (predictor II)Non-inhibitor0.9016
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point-35 °CPhysProp
boiling point105 °CPhysProp
water solubility2.83E+004 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.21HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility6.46 mg/mLALOGPS
logP2.01ALOGPS
logP2.31ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity27.97 m3·mol-1ChemAxon
Polarizability11.46 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.12 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-9100000000-e9387eb71a01da84865eView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02BG09
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.9 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Methoxyflurane can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methoxyflurane.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methoxyflurane.
AmiodaroneThe metabolism of Methoxyflurane can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amperozide.
AprepitantThe serum concentration of Methoxyflurane can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aripiprazole.
ArtemetherThe metabolism of Methoxyflurane can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Asenapine.
AtazanavirThe metabolism of Methoxyflurane can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Methoxyflurane can be decreased when combined with Atomoxetine.
Atracurium besylateMethoxyflurane may increase the neuromuscular blocking activities of Atracurium besylate.
AzaperoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Azaperone.
AzelastineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methoxyflurane.
AzithromycinThe metabolism of Methoxyflurane can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Benzyl alcohol.
BetaxololThe metabolism of Methoxyflurane can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Methoxyflurane can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Methoxyflurane can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Methoxyflurane can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Methoxyflurane can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
BrimonidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methoxyflurane.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methoxyflurane.
BupropionThe metabolism of Methoxyflurane can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methoxyflurane.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methoxyflurane.
ButacaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methoxyflurane.
CaffeineThe metabolism of Methoxyflurane can be decreased when combined with Caffeine.
CapecitabineThe metabolism of Methoxyflurane can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methoxyflurane.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carisoprodol.
CelecoxibThe metabolism of Methoxyflurane can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Methoxyflurane can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methoxyflurane.
ChlormezanoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloroprocaine.
ChloroquineThe metabolism of Methoxyflurane can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorphenamine.
ChlorpromazineThe metabolism of Methoxyflurane can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Methoxyflurane can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Methoxyflurane can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Methoxyflurane can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methoxyflurane.
CitalopramThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Citalopram.
CitalopramThe metabolism of Methoxyflurane can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Methoxyflurane can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Methoxyflurane can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clidinium.
ClobazamThe metabolism of Methoxyflurane can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clomipramine.
ClomipramineThe metabolism of Methoxyflurane can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonidine.
ClopidogrelThe metabolism of Methoxyflurane can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methoxyflurane.
ClotrimazoleThe metabolism of Methoxyflurane can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Methoxyflurane can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clozapine.
CobicistatThe serum concentration of Methoxyflurane can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methoxyflurane.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methoxyflurane.
ConivaptanThe serum concentration of Methoxyflurane can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Methoxyflurane can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methoxyflurane.
CyclosporineThe metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Methoxyflurane can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Methoxyflurane can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methoxyflurane.
DapoxetineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dapoxetine.
DarifenacinThe metabolism of Methoxyflurane can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Methoxyflurane can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Methoxyflurane can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Methoxyflurane can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Methoxyflurane can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desflurane.
DesipramineThe metabolism of Methoxyflurane can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Detomidine.
DexamethasoneThe serum concentration of Methoxyflurane can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methoxyflurane.
DextromoramideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methoxyflurane.
DezocineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methoxyflurane.
DifenoxinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Methoxyflurane can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydromorphine.
DiltiazemThe metabolism of Methoxyflurane can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Methoxyflurane can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Diphenoxylate.
DisulfiramThe metabolism of Methoxyflurane can be decreased when combined with Disulfiram.
DopamineMethoxyflurane may increase the arrhythmogenic activities of Dopamine.
DoramectinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Doxepin.
DoxorubicinThe metabolism of Methoxyflurane can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Methoxyflurane can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
DoxylamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
DronedaroneThe metabolism of Methoxyflurane can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methoxyflurane.
DrotebanolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Drotebanol.
DuloxetineThe metabolism of Methoxyflurane can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane.
EcgonineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Methoxyflurane can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Efavirenz.
EliglustatThe metabolism of Methoxyflurane can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methoxyflurane.
EntacaponeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Entacapone.
EnzalutamideThe serum concentration of Methoxyflurane can be decreased when it is combined with Enzalutamide.
EphedraEphedra may increase the arrhythmogenic activities of Methoxyflurane.
EphedrineEphedrine may increase the arrhythmogenic activities of Methoxyflurane.
EpinephrineMethoxyflurane may increase the arrhythmogenic activities of Epinephrine.
ErythromycinThe metabolism of Methoxyflurane can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Methoxyflurane can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methoxyflurane.
EthanolMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methoxyflurane.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methoxyflurane.
EthosuximideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methoxyflurane.
EtoperidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Etorphine.
EtravirineThe serum concentration of Methoxyflurane can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methoxyflurane.
FexofenadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flibanserin.
FloxuridineThe metabolism of Methoxyflurane can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Methoxyflurane can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flunitrazepam.
FluorouracilThe metabolism of Methoxyflurane can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluoxetine.
FluoxetineThe metabolism of Methoxyflurane can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methoxyflurane.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methoxyflurane.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methoxyflurane.
FluspirileneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Methoxyflurane can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluvoxamine.
FluvoxamineThe metabolism of Methoxyflurane can be decreased when combined with Fluvoxamine.
FormoterolMethoxyflurane may increase the arrhythmogenic activities of Formoterol.
FosamprenavirThe metabolism of Methoxyflurane can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Methoxyflurane can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fospropofol.
Fusidic AcidThe serum concentration of Methoxyflurane can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methoxyflurane.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Methoxyflurane can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methoxyflurane.
HaloperidolThe metabolism of Methoxyflurane can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methoxyflurane.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methoxyflurane.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
HydroxyzineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Hydroxyzine.
IdelalisibThe serum concentration of Methoxyflurane can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Iloperidone.
ImatinibThe metabolism of Methoxyflurane can be decreased when combined with Imatinib.
ImipramineThe metabolism of Methoxyflurane can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Indalpine.
IndinavirThe metabolism of Methoxyflurane can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Methoxyflurane can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Methoxyflurane can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methoxyflurane.
IsoniazidThe metabolism of Methoxyflurane can be decreased when combined with Isoniazid.
IsoprenalineMethoxyflurane may increase the arrhythmogenic activities of Isoprenaline.
IsradipineThe metabolism of Methoxyflurane can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Methoxyflurane can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Methoxyflurane can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketobemidone.
KetoconazoleThe metabolism of Methoxyflurane can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lamotrigine.
LeflunomideThe metabolism of Methoxyflurane can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methoxyflurane.
LevocabastineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methoxyflurane.
LidocaineThe metabolism of Methoxyflurane can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lofentanil.
LopinavirThe metabolism of Methoxyflurane can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methoxyflurane.
LorcaserinThe metabolism of Methoxyflurane can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Methoxyflurane can be decreased when combined with Losartan.
LovastatinThe metabolism of Methoxyflurane can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methoxyflurane.
Lu AA21004The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lu AA21004.
LuliconazoleThe serum concentration of Methoxyflurane can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Methoxyflurane can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Methoxyflurane can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methoxyflurane.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methoxyflurane.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methoxyflurane.
MetaxaloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Metaxalone.
MethadoneThe metabolism of Methoxyflurane can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methoxyflurane.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methotrimeprazine.
MethsuximideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methsuximide.
MethylphenidateMethylphenidate may increase the hypertensive activities of Methoxyflurane.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methoxyflurane.
MetoprololThe metabolism of Methoxyflurane can be decreased when combined with Metoprolol.
MetyrosineMethoxyflurane may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Methoxyflurane can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methoxyflurane.
MifepristoneThe metabolism of Methoxyflurane can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
MirabegronThe metabolism of Methoxyflurane can be decreased when combined with Mirabegron.
MirtazapineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methoxyflurane.
MitotaneThe serum concentration of Methoxyflurane can be decreased when it is combined with Mitotane.
MivacuriumMethoxyflurane may increase the neuromuscular blocking activities of Mivacurium.
ModafinilThe serum concentration of Methoxyflurane can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methoxyflurane.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.
NabiloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nabilone.
NafcillinThe serum concentration of Methoxyflurane can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methoxyflurane.
NefazodoneThe metabolism of Methoxyflurane can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Methoxyflurane can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Methoxyflurane can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Methoxyflurane can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Methoxyflurane can be decreased when combined with Nicardipine.
NicotineThe metabolism of Methoxyflurane can be decreased when combined with Nicotine.
NilotinibThe metabolism of Methoxyflurane can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nitrous oxide.
NorepinephrineMethoxyflurane may increase the arrhythmogenic activities of Norepinephrine.
NormethadoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Olanzapine.
OlaparibThe metabolism of Methoxyflurane can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Olopatadine.
OmeprazoleThe metabolism of Methoxyflurane can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methoxyflurane.
OpiumThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Opium.
OrphenadrineMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methoxyflurane.
OsanetantThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Osanetant.
OsimertinibThe serum concentration of Methoxyflurane can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methoxyflurane.
OxprenololThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methoxyflurane.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methoxyflurane.
OxymorphoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxymorphone.
PalbociclibThe serum concentration of Methoxyflurane can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Paliperidone.
PanobinostatThe metabolism of Methoxyflurane can be decreased when combined with Panobinostat.
ParaldehydeMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methoxyflurane.
ParoxetineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Paroxetine.
ParoxetineThe metabolism of Methoxyflurane can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Methoxyflurane can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methoxyflurane.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methoxyflurane.
PerampanelThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methoxyflurane.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methoxyflurane.
PhenobarbitalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pomalidomide.
PosaconazoleThe metabolism of Methoxyflurane can be decreased when combined with Posaconazole.
PramipexoleMethoxyflurane may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methoxyflurane.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methoxyflurane.
PrimidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methoxyflurane.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methoxyflurane.
PromazineThe metabolism of Methoxyflurane can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methoxyflurane.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methoxyflurane.
PropoxycaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Methoxyflurane is combined with PSD502.
PyrimethamineThe metabolism of Methoxyflurane can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Methoxyflurane can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Quetiapine.
QuinidineThe metabolism of Methoxyflurane can be decreased when combined with Quinidine.
QuinineThe metabolism of Methoxyflurane can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ramelteon.
RanolazineThe metabolism of Methoxyflurane can be decreased when combined with Ranolazine.
RapacuroniumMethoxyflurane may increase the neuromuscular blocking activities of Rapacuronium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methoxyflurane.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methoxyflurane.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methoxyflurane.
RifabutinThe metabolism of Methoxyflurane can be increased when combined with Rifabutin.
RifampicinThe metabolism of Methoxyflurane can be increased when combined with Rifampicin.
RifapentineThe metabolism of Methoxyflurane can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methoxyflurane.
RitonavirThe metabolism of Methoxyflurane can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Methoxyflurane can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Romifidine.
RopiniroleMethoxyflurane may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Methoxyflurane can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methoxyflurane.
RotigotineMethoxyflurane may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methoxyflurane.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Methoxyflurane can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methoxyflurane.
SertindoleThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sertraline.
SertralineThe metabolism of Methoxyflurane can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sevoflurane.
SildenafilThe metabolism of Methoxyflurane can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Methoxyflurane can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Methoxyflurane can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sodium oxybate.
SorafenibThe metabolism of Methoxyflurane can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Methoxyflurane can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.
SulfadiazineThe metabolism of Methoxyflurane can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Methoxyflurane can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Methoxyflurane can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methoxyflurane.
SuvorexantThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tasimelteon.
TelaprevirThe metabolism of Methoxyflurane can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Methoxyflurane can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methoxyflurane.
TenofovirThe metabolism of Methoxyflurane can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Methoxyflurane can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Methoxyflurane can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrodotoxin.
ThalidomideMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methoxyflurane.
TheophyllineThe metabolism of Methoxyflurane can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methoxyflurane.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methoxyflurane.
ThiotepaThe metabolism of Methoxyflurane can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiagabine.
TicagrelorThe metabolism of Methoxyflurane can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Methoxyflurane can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiletamine.
TipranavirThe metabolism of Methoxyflurane can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tizanidine.
TocilizumabThe serum concentration of Methoxyflurane can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Methoxyflurane can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methoxyflurane.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Methoxyflurane can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methoxyflurane.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methoxyflurane.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methoxyflurane.
TrimethoprimThe metabolism of Methoxyflurane can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methoxyflurane.
ValsartanThe metabolism of Methoxyflurane can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Methoxyflurane can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Methoxyflurane can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Methoxyflurane can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vilazodone.
VoriconazoleThe metabolism of Methoxyflurane can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Xylazine.
ZafirlukastThe metabolism of Methoxyflurane can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methoxyflurane.
ZiconotideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zimelidine.
ZiprasidoneThe metabolism of Methoxyflurane can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methoxyflurane.
ZonisamideThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Moody EJ, Suzdak PD, Paul SM, Skolnick P: Modulation of the benzodiazepine/gamma-aminobutyric acid receptor chloride channel complex by inhalation anesthetics. J Neurochem. 1988 Nov;51(5):1386-93. [PubMed:2459308 ]
  4. Moody EJ, Skolnick P: The imidazobenzodiazepine Ro 15-4513 antagonizes methoxyflurane anesthesia. Life Sci. 1988;43(16):1269-76. [PubMed:2845216 ]
  5. Krasowski MD, Harrison NL: The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations. Br J Pharmacol. 2000 Feb;129(4):731-43. [PubMed:10683198 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin DC, Plagenhoef M, Abraham J, Dennison RL, Aronstam RS: Volatile anesthetics and glutamate activation of N-methyl-D-aspartate receptors. Biochem Pharmacol. 1995 Mar 15;49(6):809-17. [PubMed:7702639 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmitter-gated ion channel activity
Specific Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name:
GLRA1
Uniprot ID:
P23415
Molecular Weight:
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Krasowski MD, Harrison NL: The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations. Br J Pharmacol. 2000 Feb;129(4):731-43. [PubMed:10683198 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Signal transducer activity
Specific Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name:
ATP2C1
Uniprot ID:
P98194
Molecular Weight:
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lopez MM, Kosk-Kosicka D: How do volatile anesthetics inhibit Ca(2+)-ATPases? J Biol Chem. 1995 Nov 24;270(47):28239-45. [PubMed:7499320 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Elliott JR, Elliott AA, Harper AA, Winpenny JP: Effects of general anaesthetics on neuronal sodium and potassium channels. Gen Pharmacol. 1992 Nov;23(6):1005-11. [PubMed:1336744 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Transporter activity
Specific Function:
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked toget...
Gene Name:
ATP5D
Uniprot ID:
P30049
Molecular Weight:
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
MT-ND1
Uniprot ID:
P03886
Molecular Weight:
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23